CA3123333A1 - 2-fluorinated bile acids for the treatment of neurodegenerative diseases - Google Patents
2-fluorinated bile acids for the treatment of neurodegenerative diseases Download PDFInfo
- Publication number
- CA3123333A1 CA3123333A1 CA3123333A CA3123333A CA3123333A1 CA 3123333 A1 CA3123333 A1 CA 3123333A1 CA 3123333 A CA3123333 A CA 3123333A CA 3123333 A CA3123333 A CA 3123333A CA 3123333 A1 CA3123333 A1 CA 3123333A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- general formula
- dihydroxy
- acid
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820887.6 | 2018-12-20 | ||
| GBGB1820887.6A GB201820887D0 (en) | 2018-12-20 | 2018-12-20 | Compounds |
| PCT/GB2019/053665 WO2020128514A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3123333A1 true CA3123333A1 (en) | 2020-06-25 |
Family
ID=65364420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3123333A Pending CA3123333A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220073557A1 (https=) |
| EP (1) | EP3898645B1 (https=) |
| JP (1) | JP7503063B2 (https=) |
| KR (1) | KR102856276B1 (https=) |
| CN (1) | CN113330020B (https=) |
| AU (1) | AU2019411556B2 (https=) |
| BR (1) | BR112021011189A2 (https=) |
| CA (1) | CA3123333A1 (https=) |
| EA (1) | EA202191521A1 (https=) |
| ES (1) | ES3036094T3 (https=) |
| GB (1) | GB201820887D0 (https=) |
| IL (1) | IL284093B2 (https=) |
| MX (1) | MX2021007551A (https=) |
| SG (1) | SG11202105465WA (https=) |
| WO (1) | WO2020128514A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486318A4 (en) * | 2022-03-02 | 2026-02-25 | Boyce Thompson Institute For Plant Res Inc | Cysteamides, related therapeutic compositions and associated processes |
| GB202208151D0 (en) | 2022-06-01 | 2022-07-13 | Nzp Uk Ltd | Compounds |
| GB202314563D0 (en) | 2023-09-22 | 2023-11-08 | Nzp Uk Ltd | Compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| FR2934596B1 (fr) * | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| ITMI20121344A1 (it) * | 2012-07-31 | 2014-02-01 | Erregierre Spa | Processo di preparazione di acido ursodesossicolico ad elevata purezza |
| WO2014036377A1 (en) | 2012-08-31 | 2014-03-06 | Metselex | Methods of promoting cell viability |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| US11072630B2 (en) * | 2015-03-10 | 2021-07-27 | Metselex, Inc. | Fluorinated and alkylated bile acids |
| GB201812382D0 (en) * | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
-
2018
- 2018-12-20 GB GBGB1820887.6A patent/GB201820887D0/en not_active Ceased
-
2019
- 2019-12-20 WO PCT/GB2019/053665 patent/WO2020128514A1/en not_active Ceased
- 2019-12-20 CA CA3123333A patent/CA3123333A1/en active Pending
- 2019-12-20 ES ES19831850T patent/ES3036094T3/es active Active
- 2019-12-20 AU AU2019411556A patent/AU2019411556B2/en active Active
- 2019-12-20 KR KR1020217019166A patent/KR102856276B1/ko active Active
- 2019-12-20 SG SG11202105465WA patent/SG11202105465WA/en unknown
- 2019-12-20 MX MX2021007551A patent/MX2021007551A/es unknown
- 2019-12-20 US US17/415,216 patent/US20220073557A1/en active Pending
- 2019-12-20 EP EP19831850.3A patent/EP3898645B1/en active Active
- 2019-12-20 CN CN201980085276.5A patent/CN113330020B/zh active Active
- 2019-12-20 JP JP2021535715A patent/JP7503063B2/ja active Active
- 2019-12-20 EA EA202191521A patent/EA202191521A1/ru unknown
- 2019-12-20 IL IL284093A patent/IL284093B2/en unknown
- 2019-12-20 BR BR112021011189-1A patent/BR112021011189A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL284093B1 (en) | 2025-03-01 |
| EP3898645C0 (en) | 2025-06-25 |
| AU2019411556A1 (en) | 2021-06-10 |
| WO2020128514A1 (en) | 2020-06-25 |
| IL284093A (en) | 2021-08-31 |
| EP3898645B1 (en) | 2025-06-25 |
| GB201820887D0 (en) | 2019-02-06 |
| KR20210125982A (ko) | 2021-10-19 |
| EP3898645A1 (en) | 2021-10-27 |
| CN113330020A (zh) | 2021-08-31 |
| ES3036094T3 (en) | 2025-09-12 |
| BR112021011189A2 (pt) | 2021-08-31 |
| JP2022514401A (ja) | 2022-02-10 |
| AU2019411556B2 (en) | 2025-04-03 |
| MX2021007551A (es) | 2021-10-13 |
| EA202191521A1 (ru) | 2021-09-10 |
| IL284093B2 (en) | 2025-07-01 |
| CN113330020B (zh) | 2024-04-05 |
| US20220073557A1 (en) | 2022-03-10 |
| JP7503063B2 (ja) | 2024-06-19 |
| SG11202105465WA (en) | 2021-06-29 |
| KR102856276B1 (ko) | 2025-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2638023B1 (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same | |
| CN114292272A (zh) | 一种核苷类化合物及其用途 | |
| AU2011343466B2 (en) | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| CN111295372B (zh) | 硝羟喹啉前药及其用途 | |
| JP2021127346A (ja) | ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用 | |
| CN118451059A (zh) | 用于rna递送的可电离阳离子脂质 | |
| JP2005522430A (ja) | グランザイムｂ阻害剤 | |
| CA3123333A1 (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| US20170354639A1 (en) | Diterpenoid derivatives and methods of use thereof | |
| CN111818798A (zh) | 索布替罗的衍生物 | |
| KR20190134722A (ko) | 치료 화합물 및 방법 | |
| CN121511234A (zh) | 用于rna递送的可电离阳离子脂质 | |
| JP2008530074A (ja) | Ｈｍ７４ａ受容体アゴニストとしてのアントラニル酸誘導体 | |
| CN112218878A (zh) | Ntcp抑制剂 | |
| WO2023233164A1 (en) | 3-azasteroid compounds for the treatment of diseases related to mitochondrial function | |
| HK40062202B (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| HK40062202A (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| EA046372B1 (ru) | 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний | |
| CN113620967B (zh) | 一种α-倒捻子素衍生物及其制备方法和应用 | |
| US5516921A (en) | Thiono-lactone inhibitors of protein trafficking and uses therefor | |
| US20260048036A1 (en) | Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof | |
| WO2025062143A1 (en) | 7-difluorinated steroids for use in the treatment of neurological or mitochondrial diseases | |
| WO2023077977A1 (zh) | 秋水仙碱衍生物的制备方法及其用途 | |
| ITMI950804A1 (it) | Composti lattonici utili per il trattamento dell'osteoporosi | |
| HK1189878B (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220912 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241212 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241212 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250204 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250604 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250606 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250730 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250730 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251126 |